1E
11.1.2022 14:12:14 CET | Business Wire | Press release
1E , the leader in Digital Employee Experience (DEX), today appointed six new senior leaders in response to booming growth in the DEX category as organizations increasingly prioritize supporting the hybrid and remote work needs of employees.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005732/en/
“2022 is going to be an epic year for 1E. We start the year on the heels of our biggest quarter ever and the launch of the latest generation of our SaaS Digital Employee Experience platform, 1E Tachyon. We've also seen significant tailwinds as DEX has become a major boardroom priority as a way to understand employee engagement, happiness and productivity in uncertain times” said Mark Banfield, CEO of 1E. “These new appointments, half of whom are women, are a key piece of the puzzle in our aggressive growth strategy and will propel us to new heights as we lead the way in writing DEX history.”
Building an organization acutely focused on customer success was paramount to 1E’s business transformation. This new approach puts 1E customers at the center so that they are better equipped to support and improve the digital experience of their employees. 1E is also doubling down on product and technology. These new additions are reflective of this strategy.
New appointments include:
● Marie Palmer, Chief Customer Officer
● Ian Van Reenen, Chief Technology Officer
● Amy Collins, Senior Vice President, Product
● Alice Carlisle, Vice President, Sales for EMEA
● Lucas Ryder, Vice President, Sales for North America
● Jason Keogh, Field CTO
Marie Palmer joins as 1E’s Chief Customer Officer. Marie, who has over fifteen years of experience leading customer success teams, the last six of which were devoted to leading customer success for VMWare in EMEA and APAC.
Ian Van Reenen joins 1E as Chief Technology Officer. Ian, a veteran technologist, has over 20 years’ experience building products to help IT departments offer a more secure, efficient, and better service at companies such as Datto, Autotask and CentraStage.
Amy Collins has been promoted to Senior Vice President, Product. Amy has worked in the technology sector for 20 years and has spent most of this time in product roles building software products in fast growth, disruptive technology companies such as Brandwatch and Signal AI.
Alice Carlisle and Lucas Ryder join as Vice President of Sales for EMEA and North America respectively. Carlisle joins most recently from LogicMonitor, where she achieved significant growth in EMEA sales, and Ryder joins from Darktrace, where he ran sales in North America. Both worked together previously at Autotask and Datto.
Jason Keogh has been promoted to Field CTO to help 1E customers map their DEX requirements back to technology solutions and to build a feedback loop between the customer base and product team. Prior to joining 1E, Jason was founder and CTO of iQuate.
About 1E
1E are the innovators in Digital Employee Experience (DEX) that supports the work from anywhere enterprise, so employees are secure, supported, and productive wherever they want to be. The 1E Tachyon Platform provides real-time diagnosis, remediation and automation that fixes issues, fast and without interruption. It puts employees in control, through self-service, self-heal and sentiment monitoring to understand how they really feel and reduces help desk calls and ultimately costs. That’s why more than 500 organizations in 42 countries trust 1E to help them manage 11 million endpoints seamlessly. For more information, visit www.1E.com .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005732/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
